Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome. [electronic resource]
Producer: 20140930Description: 1313-20 p. digitalISSN:- 1462-0332
- Adult
- Aged
- Antibodies, Monoclonal, Murine-Derived -- pharmacology
- Antirheumatic Agents -- pharmacology
- Apoptosis -- drug effects
- Female
- Humans
- In Vitro Techniques
- Interferons
- Interleukin-17 -- metabolism
- Interleukin-23 -- metabolism
- Interleukins -- metabolism
- Male
- Mast Cells -- drug effects
- Middle Aged
- Rituximab
- STAT3 Transcription Factor
- Salivary Glands -- drug effects
- Signal Transduction -- drug effects
- Sjogren's Syndrome -- drug therapy
- Th17 Cells -- drug effects
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.